Current Report Filing (8-k)
September 26 2017 - 7:02AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date of Report (Date
of earliest event reported):
September 26, 2017
ASSEMBLY BIOSCIENCES, INC.
(Exact name of registrant as specified in
its charter)
Delaware
|
|
001-35005
|
|
20-8729264
|
(State or other jurisdiction of
incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
11711 N. Meridian St., Suite 310
Carmel,
Indiana 46032
(Address of principal executive offices, including zip code)
(317) 210-9311
(Registrant’s telephone number, including
area code)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
|
Item 7.01
|
Regulation FD Disclosure.
|
Assembly Biosciences, Inc. (the “Company”)
is furnishing a corporate presentation, attached as Exhibit 99.1 to this Current Report on Form 8-K, that the Company intends to
use from time to time in meetings with investors and others beginning on September 26, 2017. The corporate presentation will also
be available on the Company’s website at http://investor.assemblybio.com/events.cfm.
The information in this Item 7.01 and Exhibit
99.1 attached hereto is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange
Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it
be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
The following exhibit relating to Item 7.01
shall be deemed furnished and not filed.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: September 26, 2017
|
Assembly Biosciences, Inc.
|
|
|
|
|
|
|
|
By:
|
/s/ Derek A. Small
|
|
|
Derek A. Small
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Assembly Biosciences (NASDAQ:ASMB)
Historical Stock Chart
From Apr 2023 to Apr 2024